149 related articles for article (PubMed ID: 3472902)
1. Review of clinical and haematological response to low-dose cytosine arabinoside in acute myeloid leukaemia.
Shtalrid M; Lotem J; Sachs L; Berrebi A
Eur J Haematol; 1987 Jan; 38(1):3-11. PubMed ID: 3472902
[TBL] [Abstract][Full Text] [Related]
2. Low-dose arabinosyl cytosine therapy of AML may be effective after failure of high or conventional doses.
Tertian G; Tchernia G; Léonard C; Miélot F; Avalos M; Mirica C; Brivet F; Dommergues JP
Nouv Rev Fr Hematol (1978); 1989; 31(4):311-3. PubMed ID: 2608442
[TBL] [Abstract][Full Text] [Related]
3. In vivo differentiation of leukaemic blasts and effect of low dose Ara-C in a marrow grafted patient with leukaemic relapse.
Mittermüller J; Kolb HJ; Gerhartz HH; Wilmanns W
Br J Haematol; 1986 Apr; 62(4):757-62. PubMed ID: 2938618
[TBL] [Abstract][Full Text] [Related]
4. Low-dose ARA-C fails to enhance differentiation of leukaemic cells.
Perri RT; Weisdorf DJ; Oken MM
Br J Haematol; 1985 Apr; 59(4):697-701. PubMed ID: 3886002
[TBL] [Abstract][Full Text] [Related]
5. Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction.
Leyden M; Manoharan A; Boyd A; Cheng ZM; Sullivan J
Br J Haematol; 1984 Jun; 57(2):301-7. PubMed ID: 6587903
[TBL] [Abstract][Full Text] [Related]
6. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
Jehn U; Göldel N; Vehling-Kaiser U
Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
[TBL] [Abstract][Full Text] [Related]
7. [High dosage and intermediate dosage cytosine arabinoside in the treatment of secondary leukemias].
Leitha T; Jäger U; Schwarzinger I; Bettelheim P; Hinterberger W; Neumann E; Korninger C; Kyrle PA; Haas O; Schlappack O
Wien Klin Wochenschr; 1988 Aug; 100(15):509-14. PubMed ID: 3176503
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
[TBL] [Abstract][Full Text] [Related]
9. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy with low-dose cytosine arabinoside in refractory or relapsed acute non-lymphocytic leukaemia: a report on 25 patients.
Jensen MK; Johansen P; Stentoft J; Jensen MK
Eur J Haematol; 1994 Apr; 52(4):236-9. PubMed ID: 8005235
[TBL] [Abstract][Full Text] [Related]
13. In vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: growth pattern and drug sensitivity.
Marie JP; Zittoun R; Thevenin D; Mathieu M; Viguie F
Br J Haematol; 1983 Nov; 55(3):427-37. PubMed ID: 6580036
[TBL] [Abstract][Full Text] [Related]
14. The results of treatment of selected patients with ANLL with low-dose Ara-C.
Pawelski S; Brodzki LM; Gepner-Woźniewska M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(1):71-4. PubMed ID: 2472330
[TBL] [Abstract][Full Text] [Related]
15. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly H; Castaigne S; Bordessoule D; Casassus P; Le Prisé PY; Tertian G; Desablens B; Henry-Amar M; Degos L
J Clin Oncol; 1990 Feb; 8(2):272-9. PubMed ID: 2299370
[TBL] [Abstract][Full Text] [Related]
16. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
Loeb DM; Bowers DC; Civin CI; Friedman AD
Med Pediatr Oncol; 2001 Oct; 37(4):365-71. PubMed ID: 11568900
[TBL] [Abstract][Full Text] [Related]
17. Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
van Geel BM; Huijgens PC; Ossenkoppele GJ; Wijermans PW; Langenhuijsen MM
Neth J Med; 1989 Oct; 35(3-4):128-36. PubMed ID: 2601790
[TBL] [Abstract][Full Text] [Related]
18. A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: preclinical cell culture studies.
Curtis JE; Minkin S; Minden MD; McCulloch EA
Br J Haematol; 1996 Nov; 95(2):354-63. PubMed ID: 8904892
[TBL] [Abstract][Full Text] [Related]
19. [High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study].
Ritter J; Creutzig U; Henze G; Jürgens H; Bode U; Prindull G; Schellong G
Onkologie; 1987 Feb; 10(1):24-7. PubMed ID: 3295622
[TBL] [Abstract][Full Text] [Related]
20. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
